Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

V1RC15 Inhibitors

V1RC15 inhibitors constitute a class of chemical compounds designed to selectively interact with a particular biological target, typically a protein or enzyme, which is identified by the code V1RC15. The function of inhibitors in general is to bind to their targets with high specificity and affinity, which results in the modulation of the activity of the target. By doing so, they can alter the conformation, functionality, or stability of the target molecule, often leading to a decrease in its activity or an alteration in its interaction with other molecules within a biological system.

The design of V1RC15 inhibitors typically involves a thorough understanding of the molecular structure of the V1RC15 target. This could include knowledge about the active sites, binding pockets, or allosteric sites on the protein that are crucial for its function. Using techniques such as X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy, scientists are able to determine the three-dimensional arrangement of atoms within the target and thus identify potential sites for inhibitor binding. Chemical inhibitors are then crafted through a combination of medicinal chemistry, computational modeling, and iterative synthesis to achieve a molecule that fits snugly into the target site. This "lock-and-key" interaction is fundamental to the inhibitor's ability to modulate the target's activity. The compounds may also be optimized for desirable pharmacokinetic properties, ensuring that they are stable and can reach their target in the biological context for which they are designed. The development of V1RC15 inhibitors typically requires a multi-disciplinary approach involving chemistry, biology, and computational science.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A potent inhibitor of PI3K, which is upstream of AKT. Inhibition of PI3K leads to reduced AKT phosphorylation, indirectly decreasing the activity of V1RC15 if it is AKT-dependent.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor that can downregulate protein synthesis and cell growth, potentially reducing V1RC15 activity if V1RC15 is involved in these cellular processes.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor that can interfere with stress-activated protein kinase pathways, indirectly affecting V1RC15 if it is linked to these pathways.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

An MEK inhibitor, which blocks the MAPK/ERK pathway. If V1RC15 operates downstream of this pathway, its activity would be impaired.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

A PI3K inhibitor like LY294002, leading to decreased AKT activity and potentially decreasing V1RC15 activity if V1RC15 is regulated by AKT.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Another MEK inhibitor that impedes the MAPK/ERK pathway, indirectly diminishing V1RC15 activity if it is part of this pathway.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

A Src family kinase inhibitor that could reduce V1RC15 activity by inhibiting upstream signaling pathways that involve Src kinases.

PP242

1092351-67-1sc-301606A
sc-301606
1 mg
5 mg
$56.00
$169.00
8
(1)

An mTOR kinase inhibitor that can suppress mTORC1 and mTORC2, potentially affecting V1RC15 if it is involved in mTOR signaling pathways.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

An inhibitor of JNK, which could lead to decreased V1RC15 activity if V1RC15 is involved in JNK signaling pathways.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor that could lead to a buildup of proteins targeted for degradation, potentially affecting V1RC15 if it is regulated through proteasomal degradation.